The m
RNA N6-methyladenosine
immune infiltration
molecular characterization
prognosis
prostate adenocarcinoma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
11
2022
accepted:
09
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
Despite the recent progress of therapeutic strategies in treating prostate cancer (PCa), the majority of patients still eventually relapse, experiencing dismal outcomes. Therefore, it is of utmost importance to identify novel viable targets to increase the effectiveness of treatment. The present study aimed to investigate the potential relationship between N6-methyladenosine (m6A) RNA modification and PCa development and determine its clinical relevance. Through systematic analysis of the TCGA database and other datasets, we analyzed the gene expression correlation and mutation profiles of m6A-related genes between PCa and normal tissues. Patient samples were divided into high- and low-risk groups based on the results of Least Absolute Shrinkage and Selection Operator (LASSO) Cox analysis. Subsequently, differences in biological processes and genomic characteristics of the two risk groups were determined, followed by functional enrichment analysis and gene set enrichment (GSEA) analysis. Next, we constructed the protein-protein interaction (PPI) network of differentially expressed genes between patients in high- and low-risk groups, along with the mRNA-miRNA-lncRNA network. The correlation analysis of tumor-infiltrating immune cells was further conducted to reveal the differences in immune characteristics between the two groups. A variety of m6A-related genes were identified to be differentially expressed in PCa tissues as compared with normal tissues. In addition, the PPI network contained 278 interaction relationships and 34 m6A-related genes, and the mRNA-miRNA-lncRNA network contained 17 relationships, including 91 miRNAs. Finally, the immune characteristics analysis showed that compared with the low-risk group, the levels of M1 and M2 macrophages in the high-risk group significantly increased, while the levels of mast cells resting and T cells CD4 memory resting significantly decreased. This study provides novel findings that can further the understanding of the role of m6A methylation during the progression of PCa, which may facilitate the invention of targeted therapeutic drugs.
Sections du résumé
Background
Despite the recent progress of therapeutic strategies in treating prostate cancer (PCa), the majority of patients still eventually relapse, experiencing dismal outcomes. Therefore, it is of utmost importance to identify novel viable targets to increase the effectiveness of treatment. The present study aimed to investigate the potential relationship between N6-methyladenosine (m6A) RNA modification and PCa development and determine its clinical relevance.
Methods
Through systematic analysis of the TCGA database and other datasets, we analyzed the gene expression correlation and mutation profiles of m6A-related genes between PCa and normal tissues. Patient samples were divided into high- and low-risk groups based on the results of Least Absolute Shrinkage and Selection Operator (LASSO) Cox analysis. Subsequently, differences in biological processes and genomic characteristics of the two risk groups were determined, followed by functional enrichment analysis and gene set enrichment (GSEA) analysis. Next, we constructed the protein-protein interaction (PPI) network of differentially expressed genes between patients in high- and low-risk groups, along with the mRNA-miRNA-lncRNA network. The correlation analysis of tumor-infiltrating immune cells was further conducted to reveal the differences in immune characteristics between the two groups.
Results
A variety of m6A-related genes were identified to be differentially expressed in PCa tissues as compared with normal tissues. In addition, the PPI network contained 278 interaction relationships and 34 m6A-related genes, and the mRNA-miRNA-lncRNA network contained 17 relationships, including 91 miRNAs. Finally, the immune characteristics analysis showed that compared with the low-risk group, the levels of M1 and M2 macrophages in the high-risk group significantly increased, while the levels of mast cells resting and T cells CD4 memory resting significantly decreased.
Conclusions
This study provides novel findings that can further the understanding of the role of m6A methylation during the progression of PCa, which may facilitate the invention of targeted therapeutic drugs.
Identifiants
pubmed: 37033963
doi: 10.3389/fimmu.2023.1086907
pmc: PMC10076583
doi:
Substances chimiques
RNA, Long Noncoding
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086907Informations de copyright
Copyright © 2023 Li, Peng, Gan, Zhou, Hou, Wang, Yuan, Xiong and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Med (Lausanne). 2022 Feb 03;9:824464
pubmed: 35187007
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Oncogene. 2022 Mar;41(11):1610-1621
pubmed: 35094010
J Exp Clin Cancer Res. 2018 Sep 5;37(1):219
pubmed: 30185212
EMBO Rep. 2020 Oct 5;21(10):e49863
pubmed: 32783360
Nucleic Acids Res. 2020 Jul 2;48(W1):W244-W251
pubmed: 32484539
Cell Death Discov. 2022 Apr 9;8(1):184
pubmed: 35397614
Int J Oncol. 2022 Jan;60(1):
pubmed: 34970694
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Oncotarget. 2016 Jan 12;7(2):1421-38
pubmed: 26623558
NAR Cancer. 2022 Mar 25;4(1):zcac010
pubmed: 35350771
Front Genet. 2020 Dec 04;11:602485
pubmed: 33343639
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Front Oncol. 2022 Jun 22;12:914692
pubmed: 35814454
Cell Rep. 2020 Dec 22;33(12):108544
pubmed: 33357433
Cancer Cell Int. 2021 Oct 26;21(1):569
pubmed: 34702266
Nucleic Acids Res. 2022 Jan 7;50(D1):D231-D235
pubmed: 34893873
Theranostics. 2021 Jun 11;11(16):7640-7657
pubmed: 34335955
Sci Rep. 2015 Nov 02;5:16018
pubmed: 26522007
Front Pharmacol. 2022 Oct 12;13:1030766
pubmed: 36313300
Front Immunol. 2021 Aug 31;12:735170
pubmed: 34531875
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
J Cancer. 2020 Mar 25;11(12):3588-3595
pubmed: 32284755
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cancer Gene Ther. 2023 Jan;30(1):209-218
pubmed: 36195720
Cell. 2015 Jun 4;161(6):1388-99
pubmed: 26046440
Am J Cancer Res. 2020 Mar 01;10(3):1012-1025
pubmed: 32266107
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8
pubmed: 26080435
Signal Transduct Target Ther. 2021 Feb 21;6(1):74
pubmed: 33611339
Cell Death Dis. 2023 Feb 7;14(2):91
pubmed: 36750551
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34260682
Genes Dev. 2015 Jul 1;29(13):1343-55
pubmed: 26159994
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Sci Rep. 2018 Dec 3;8(1):17546
pubmed: 30510242
Nat Rev Mol Cell Biol. 2019 Oct;20(10):608-624
pubmed: 31520073
Onco Targets Ther. 2019 Nov 05;12:9143-9152
pubmed: 31806999
Nat Cell Biol. 2021 Apr;23(4):341-354
pubmed: 33795875
Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):407-435
pubmed: 33905280
Cell Death Discov. 2022 Mar 30;8(1):143
pubmed: 35354789
Biomed Pharmacother. 2018 Aug;104:637-644
pubmed: 29803177
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Lancet Oncol. 2013 Dec;14(13):1307-16
pubmed: 24211163
J Cancer Res Clin Oncol. 2022 Jun 22;:
pubmed: 35731271
Genes Genomics. 2021 Dec;43(12):1413-1421
pubmed: 34677810
Lancet Oncol. 2022 Mar;23(3):393-405
pubmed: 35157830
Biomed Pharmacother. 2019 Apr;112:108613
pubmed: 30784918
Nat Chem Biol. 2014 Feb;10(2):93-5
pubmed: 24316715
Cancer Sci. 2023 Jan 31;:
pubmed: 36718950
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Bioorg Chem. 2019 Nov;92:103214
pubmed: 31499258
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Cancer Cell. 2016 Apr 11;29(4):536-547
pubmed: 27050099
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancer Res. 2015 Dec 15;75(24):5309-17
pubmed: 26573802
BMC Bioinformatics. 2012 Mar 13;13 Suppl 2:S11
pubmed: 22536862
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Front Mol Biosci. 2021 Dec 01;8:775304
pubmed: 34926580